Dr. Mike Moser completed medical school and surgical residency at the University of Alberta in Canada, then completed a fellowship under the mentorship of Dr. William Wall in London, Ontario in Hepatobiliary Surgery and Transplantation.

Dr. Moser currently practices in Saskatoon, at the University of Saskatchewan as a hepatobiliary and transplant surgeon and maintains a keen interest in tumor ablation and surgical education. Dr. Moser is involved in collaborative research with the Departments of Biomedical Engineering, Chemistry, Oncology, Pharmacology, and Immunology, studying ways of improving the effectiveness of the NanoKnife, while maintaining the relative safety of this novel ablation technology.

‍

Dr. Sharlene Gill is a medical oncologist specializing in gastrointestinal (GI) malignancies at BC Cancer – Vancouver.  She received a BSc. in Pharmacy, and MD from the University of British Columbia in 1996 followed by residencies in Internal Medicine and Medical Oncology, subsequently completing a fellowship in Gl Oncology at the Mayo Clinic (Rochester, MN) and a Masters of Public Health from the Harvard School of Public Health (Boston, MA) before returning to Vancouver where she is presently Professor of Medicine at the University of British Columbia.  In 2017, she completed an MBA from the Kenan-Flagler School of Business at the University of North Carolina.  Her areas of clinical expertise are in colorectal, pancreatic and hepatobiliary cancers.  She is actively engaged in education and clinical research, with over 100 peer-reviewed publications and book chapters to her credit.

‍

Dr. Hallet is an Assistant Professor of Surgery at the University of Toronto and a Surgical Oncologist at the Odette Cancer Centre - Sunnybrook Health Sciences Centre specialized in hepato-biliary, pancreatic and upper gastrointestinal malignancies, with a clinical focus on minimally invasive and image-guided therapies, as well as neuroendocrine tumours as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors. She completed her general surgery residency and MSc in Clinical Epidemiology at Université Laval in Québec City, followed by a Surgical Oncology fellowship in the hepato-pancreatio-biliary track program at the University of Toronto, and additional training in advanced minimally invasive and robotic hepato-pancreatico-biliary surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France.

As a surgeon investigator, Dr. Hallet’s research focuses on health services research to examine processes, patterns of care, and outcomes of hepato-pancreato-biliary malignancies, with a focus on patient engagement and patient-reported/patient-centred outcomes. In particular, her research is supported by operating grants from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research, as well as prior early career investigator awards from the Society of Surgery of the Alimentary Tract and the North-American Neuroendocrine Tumors Society.

‍

Dr. Robert Grant is a medical oncologist at Princess Margaret Cancer Centre who treats patients with pancreatic cancer. His research focuses on using machine learning to improve outcomes in oncology.

Popi Kasvis is a Clinical Nutritionist/Dietitian at the McGill University Health Centre in Montreal, working within the multidisciplinary Cancer Rehabilitation Program (CAREPRO). Briefly, her clinical duties include:

1) assessing patients for the presence of malnutrition/sarcopenia/cachexia.

2) creating a nutritional treatment plan to optimize nutritional status.

3) managing nutrition impact symptoms.

Any patient with cancer, including pancreatic cancer, at any stage of disease and into survivorship, may be referred to CAREPRO. Popi is also a PhD candidate in the department of Health and Exercise Science at Concordia University. Her research is focused on the effect of early diet and exercise interventions on the health-related quality of life of patients with pancreatic cancer, undergoing both curative and palliative treatments.

‍

Dr. Ramjeesingh holds an MD and PhD from the University of Toronto and completed residency training in internal medicine and medical oncology through Queen’s University. He then undertook a two-year clinical trial methodology and translational research fellowship with the NCIC Clinical Trials Group at Queen’s. His work focused on the appropriate timing of administration of adjuvant chemotherapy to patients with breast cancer.

‍

Dr. Mark Walsh MD MSc FRCSC is a Hepato-Pancreatico-Biliary surgeon at the QEII Health Sciences Centre and an Assistant Professor and Director of Quality Improvement at Dalhousie University, in Nova Scotia Canada.

Dr. Jeanette Boudreau received her PhD from McMaster University and completed post-doctoral training at Memorial Sloan Kettering Cancer Center. Dr. Boudreau’s laboratory focuses on human natural killer cells as indicators and tools for cancer immunotherapy. Her group is interested in both the genetic and functional aspects of pancreatic cancer and the immune system, and how they factor into development and treatment of cancer. The Boudreau laboratory uses high-parameter flow cytometry, microscopy and humanized animal models to study immune-tumor interactions.

‍

Mustapha Tehfe is an associate professor in the Department of Medicine at the University of Montreal and hemato-oncologist at the Center hospitalier de l'Université de Montréal (CHUM).

‍

George Zogopoulos, MD, PhD, FRCS(C), FACS is an Associate Professor of Surgery and Oncology at McGill University and a hepato-pancreato-biliary and transplant surgeon at the MUHC. He completed his clinical training at the University of Toronto, where he obtained his medical degree, followed by residency in general surgery and surgical fellowship in hepato-pancreato-biliary surgical oncology and abdominal organ transplant surgery. His research training was completed at McGill University and at the University of Toronto. He obtained his Ph.D. in Experimental Medicine at McGill University, studying the regulatory mechanisms of a gene responsible for human growth. He is a junior 2 clinical research scholar of the Fonds de recherche du Quebec and a scientist at the Research Institute of the MUHC and the GCRC. His research program is centered on the genetics and oncogenomics of pancreatic cancer, and his clinical practice is built around and driven by his research focus.

‍